April 14, 2021 -- Multiply Labs has received $20 million in investments to pioneer the robotic manufacturing of individualized drugs.
The company was founded to leverage automation to address limitations of manual processes used to manufacture small-batch pharmaceutical products. Using autonomous technology, the company enables production of individualized drugs at industrial scale. It focuses on two markets: robotic manufacturing of personalized capsules for clinical trials and robotic manufacturing of cell therapies.
The series A financing, led by Casdin Capital, will support the deployment of cloud-controlled robotic systems to enable drug production at industrial scale.